October 25, 2014 11:46 AM ET


Company Overview of Altor BioScience Corporation

Company Overview

Altor BioScience Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of immunotherapeutic agents for the treatment of cancer, viral infections, and inflammatory and autoimmune diseases. Its product candidates include ALT-801, a T-cell receptor-targeted immunotherapeutic for cancer; ALT-836, a monoclonal antibody-based tissue factor antagonist treatment of patients with acute respiratory distress syndrome and acute lung injury; and ALT-803, an IL-15 superagonist for patients with solid and hematological tumors/metastatic melanoma. The company’s product candidates also include ALT-802, a p53-TCR (T-cell receptors)/IgG1 fusion protein for treat...

2810 North Commerce Parkway

Miramar, FL 33025-3958

United States

Founded in 2002





Key Executives for Altor BioScience Corporation

Chief Financial Officer and Vice President of Business Development
Age: 65
Vice President of Research & Development
Consulting Medical Director and Member of Clinical Advisory Board
Director of Regulatory Compliance
Compensation as of Fiscal Year 2014.

Altor BioScience Corporation Key Developments

Altor BioScience Corporation Presents at BioFlorida Annual Conference, Oct-14-2014 11:15 AM

Altor BioScience Corporation Presents at BioFlorida Annual Conference, Oct-14-2014 11:15 AM. Venue: Harbor Beach Marriott, Ft. Lauderdale, Florida, United States. Speakers: Warren Marcus, Scientist and Business Development Associate.

Altor BioScience Corporation and Shenzhen Beike Biotechnology Co., Ltd Announce License Agreement for Immunotherapeutic ALT-803 in China

Altor BioScience Corporation and Shenzhen Beike Biotechnology Co. Ltd. (Beike), announced that they have entered into a license agreement to develop and commercialize ALT-803, Altor's proprietary Interleukin-15 (IL-15) based superagonist complex, in China. Under the terms of the agreement, Altor has granted Beike an exclusive license for the research, development, manufacture and commercialization of ALT-803 for therapeutic uses in all human disease indications in China. As part of the agreement, Altor will receive an up-front fee of USD 4 million and could potentially receive over USD 200 million in development and sales milestones, and tiered double-digit royalties based on sales of licensed products. Beike has also made a strategic equity investment of approximately USD 5 million into Altor. Beike will have marketing rights for licensed products in China, and Altor will retain marketing rights in all other countries.

Similar Private Companies By Industry

Company Name Region
TSI Health Sciences, Inc. United States
Vemas Herb & Health United States
Roex Inc. United States
Synthon Pharmaceuticals, Inc. United States
Carlsbad Technology, Inc. United States

Recent Private Companies Transactions

Private Placement
September 10, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Altor BioScience Corporation, please visit www.altorbioscience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.